What are Boston Scientific's total assets?

Boston Scientific (BSX) holds $44.4B in total assets, up 10.5% year over year.

How much cash does Boston Scientific have?

Boston Scientific holds $850.0M in cash and equivalents.

Can Boston Scientific cover its short-term obligations?

Its current ratio is 1.90 — current assets exceed current liabilities.

Where does Boston Scientific's balance sheet data come from?

Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Boston Scientific BSX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$850M+146%	$965M+165%	$893M+11.2%	$388M-51.1%	$345M-10.2%
Restricted cash	——	——	$98M+40.0%	$109M+45.3%	$103M+10.8%
Accounts receivable, net	$3.15B+12.4%	$3.06B+14.7%	$2.96B+13.4%	$2.93B+16.8%	$2.81B+16.3%
Inventories	$3.12B+8.7%	$2.94B+4.7%	$2.92B+6.1%	$2.86B+9.7%	$2.87B+11.9%
Raw materials	$928M+10.1%	$849M+3.7%	$849M-1.3%	$835M-1.6%	$843M+3.1%
Work in process	$259M+18.8%	$246M+27.5%	$245M+18.9%	$218M+8.5%	$218M+16.0%
Prepaid expenses and other current assets	$729M-3.6%	$660M-20.6%	$701M+4.0%	$613M-18.9%	$756M+12.7%
Income taxes receivable	$358M+21.8%	$299M-2.6%	$310M-6.6%	$298M-5.4%	$294M-7.8%
Derivative assets	——	——	——	——	$11M-91.2%
Total current assets	$8.68B+18.4%	$8.79B+27.1%	$8.04B-8.3%	$7.12B-20.8%	$7.34B-10.4%
Property and equipment, net	$4.06B+19.9%	$4.04B+22.5%	$3.8B+23.5%	$3.46B+17.3%	$3.39B+17.0%
Land	$188M+29.7%	$173M+20.1%	$147M+2.8%	$147M+5.0%	$145M+2.8%
Buildings and improvements	$2.52B+20.1%	$2.48B+23.0%	$2.54B+32.6%	$2.15B+14.7%	$2.1B+12.9%
Accumulated depreciation	$3.67B+0.9%	$3.61B+2.2%	$3.86B+6.6%	$3.78B+6.2%	$3.64B+3.2%
Goodwill	$18.54B+6.9%	$18.28B+7.0%	$18.21B+21.2%	$18.08B+25.6%	$17.34B+20.7%
Equity securities	——	——	——	——	——
Total assets	$44.35B+10.5%	$43.67B+10.9%	$42.71B+12.2%	$41.56B+12.0%	$40.14B+9.5%
Accounts payable	$1.14B+13.6%	$1.14B+19.2%	$1B+10.5%	$962M+6.2%	$1B+9.0%
Finance Lease Liability, Current	——	——	——	——	——
Total current liabilities	$4.57B-9.6%	$5.44B-15.0%	$5.33B-9.8%	$5.19B-6.9%	$5.06B+2.9%
Other non-current liabilities	$2.47B+26.9%	$2.41B+28.6%	$2.39B+29.8%	$2.38B+32.4%	$1.95B+1.4%
Total liabilities	——	——	——	——	——
Retained earnings	$6.91B+107%	$5.57B+108%	$4.9B+133%	$4.14B+153%	$3.35B+155%
Accumulated other comprehensive income (loss)	-$398M-1,321%	-$610M-322%	-$689M-438%	-$722M-540%	-$28M-121%
Total stockholders' equity	$25.86B+16.4%	$24.23B+11.3%	$23.39B+13.0%	$22.42B+10.0%	$22.21B+11.5%
Total liabilities and stockholders' equity	$44.35B+10.5%	$43.67B+10.9%	$42.71B+12.2%	$41.56B+12.0%	$40.14B+9.5%
Allowance for Doubtful Accounts	$127M+12.4%	$132M+21.1%	$133M+22.0%	$112M+6.7%	$113M+3.7%
Finished goods	$1.93B+7.0%	$1.85B+2.8%	$1.83B+8.3%	$1.81B+16.0%	$1.81B+16.1%
Derivative Assets - Fair Value	$219M-5.6%	$181M-52.9%	$125M-33.5%	$91M-70.9%	$232M-23.2%
Trading Securities in Marketable Securities	$396M+33.3%	$286M+3.2%	$310M+12.3%	$292M+20.2%	$297M+36.2%
Accumulated Goodwill Impairment Losses	$9.9B—	$9.9B—	$9.9B—	——	——
Deferred Tax Assets and Other Non-Current Assets	$2.05B+12.0%	$1.87B+6.4%	$1.83B+11.6%	$1.86B+20.2%	$1.83B+14.9%
Equity Method Investment Basis Difference	——	——	——	——	——
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments	$396M+33.3%	$286M+3.2%	$310M+12.3%	$292M+20.2%	$297M+36.2%
Indefinite-Lived Intangible Assets	$770M+719%	$813M+765%	$813M+765%	$813M+280%	$94M-46.0%
Indefinite-Lived Intangible Assets, Gross	$770M+719%	$813M+765%	$813M+765%	$813M+280%	$94M-46.0%
Indefinite-Lived Research and Development Assets	$770M+719%	$813M+765%	$813M+765%	$813M+280%	$94M-46.0%
Indefinite-Lived Trademarks	$770M+719%	$813M+765%	$813M+765%	$813M+280%	$94M-46.0%
Investments - Amortized Cost Basis	$396M+33.3%	$286M+3.2%	$310M+12.3%	$292M+20.2%	$297M+36.2%
Net Investment in Lease	$547M+22.1%	$465M+3.6%	$495M+16.2%	$492M+18.3%	$448M+4.2%
Deferred tax assets	$3.95B+7.5%	$3.68B+0.5%	$3.67B-3.9%	$3.78B-0.6%	$3.68B-3.1%
Other intangible assets—net	$7.06B+7.5%	$7.02B+5.0%	$7.16B+24.5%	$7.26B+34.0%	$6.57B+12.5%
Investments	$705M+7.6%	$681M+22.7%	$643M+20.9%	$626M+39.1%	$655M+52.7%
Operating lease right-of-use assets	$547M+22.1%	$465M+3.6%	$495M+16.2%	$492M+18.3%	$448M+4.2%
Other Assets	$44.35B—	$43.67B—	$42.71B—	——	——
Other non-current assets	$2.05B+12.0%	$1.87B+6.4%	$1.83B+11.6%	$1.86B+20.2%	$1.83B+14.9%
Property, plant and equipment, net	——	——	——	——	——
Property, plant and equipment at cost	$7.74B+10.0%	$7.65B+12.0%	$7.66B+14.4%	$7.24B+11.2%	$7.03B+9.4%
Operating Lease Right-of-Use Assets in Other Assets	$547M+22.1%	$465M+3.6%	$495M+16.2%	$492M+18.3%	$448M+4.2%
Software and Technology Licenses, Net	$2.05B+12.0%	$1.87B+6.4%	$1.83B+11.6%	$1.86B+20.2%	$1.83B+14.9%
Other Commercial Liabilities	$2.51B+6.8%	$3.2B+15.4%	$2.98B+21.2%	$2.8B+20.6%	$2.35B+13.0%
Accrued Liabilities, Current	$2.51B+6.8%	$3.2B+15.4%	$2.98B+21.2%	$2.8B+20.6%	$2.35B+13.0%
Other accrued liabilities	$875M-5.2%	$795M-10.4%	$862M-3.3%	$952M+23.6%	$923M+11.6%
Derivative Liabilities - Fair Value	$1.23B+17.5%	$1.31B+32.1%	$1.33B+22.1%	$1.42B+45.4%	$1.05B+6.2%
Supplier Finance Program Obligations	$145M+12.4%	$144M+2.9%	$151M+10.2%	$139M+6.1%	$129M-7.9%
Long-Term Debt and Finance Lease Obligations	$10.99B+4.3%	$11.14B+24.2%	$11.12B+20.4%	$11.11B+23.5%	$10.53B+10.5%
Additional paid-in capital	$21.58B+2.2%	$21.51B+2.1%	$21.42B+2.2%	$21.23B+2.1%	$21.13B+2.0%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$17M0.0%	$17M0.0%	$17M0.0%	$17M0.0%	$17M0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Treasury Stock, Value	$2.25B0.0%	$2.25B0.0%	$2.25B0.0%	$2.25B0.0%	$2.25B0.0%
Aggregate Notional Principal Outstanding	$14.63B+38.8%	$13.72B+58.8%	$13.08B+75.0%	$11.83B+71.5%	$10.54B+51.6%
Gross Assets/Liabilities	$1.23B+17.5%	$1.31B+32.1%	$1.33B+22.1%	$1.42B+45.4%	$1.05B+6.2%
Allowance for doubtful accounts	$127M+12.4%	$132M+21.1%	$133M+22.0%	$112M+6.7%	$113M+3.7%
Business Combination, Contingent Consideration, Liability	$354M+65.4%	$385M+125%	$378M+121%	$367M+25.3%	$214M-21.6%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	2B0.0%	2B0.0%	2B0.0%	2B0.0%	2B0.0%
Common stock, shares issued (in shares)	——	1.7B—	1.7B—	——	——
Construction work in progress	$1.12B+10.5%	$1.16B+12.2%	$936M-3.1%	$1.04B+16.1%	$1.01B+14.7%
Contract with Customer, Liability	$686M+7.0%	$682M+7.4%	$668M+8.1%	$662M+10.5%	$641M+8.1%
Short-term debt and current portion of long-term debt	$41M-94.7%	$299M-83.2%	$483M-70.8%	$480M-69.6%	$777M-28.4%
Debt Instrument, Fair Value Disclosure	$10.59B-2.9%	$11.15B+8.0%	$11.16B+4.0%	$11.32B+12.3%	$10.9B+6.6%
Deferred income taxes	$219M+38.6%	$220M+41.9%	$242M+75.4%	$226M+71.2%	$158M+19.7%
Derivative, gross, assets	$219M-5.6%	$181M-52.9%	$125M-33.5%	$91M-70.9%	$232M-23.2%
Derivatives, gross, liabilities	$1.23B+17.5%	$1.31B+32.1%	$1.33B+22.1%	$1.42B+45.4%	$1.05B+6.2%
Derivative Liability	——	——	——	——	——
Notional	$14.63B+38.8%	$13.72B+58.8%	$13.08B+75.0%	$11.83B+71.5%	$10.54B+51.6%
Equipment, furniture and fixtures	$3.92B+3.6%	$3.83B+5.4%	$4.04B+9.9%	$3.9B+8.5%	$3.78B+6.5%
Difference between equity method investment carrying value and book value	——	——	——	——	——
Equity method investments (Note 11)	$309M-13.7%	$396M+42.4%	$334M+30.5%	$334M+61.4%	$358M+69.7%
Trading securities, cost	$396M+33.3%	$286M+3.2%	$310M+12.3%	$292M+20.2%	$297M+36.2%
Current maturities of long-term debt	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$11.7B+8.1%	$11.46B+8.1%	$11.23B+6.7%	$11B+6.7%	$10.82B+6.1%
Gross Carrying Amount	$17.99B+4.0%	$17.67B+2.8%	$17.58B+8.6%	$17.45B+12.5%	$17.29B+9.0%
Goodwill, Gross	$28.44B—	$28.18B—	$28.11B—	——	——
Goodwill accumulated impairment losses	$9.9B—	$9.9B—	$9.9B—	——	——
Trademarks	$770M+719%	$813M+765%	$813M+765%	$813M+280%	$94M-46.0%
Legal payments remaining to be excluded from calculation of consolidated EBITDA	——	——	——	——	——
Letters of Credit Outstanding, Amount	$193M-11.5%	$203M-1.5%	$223M+3.2%	$220M+16.4%	$218M+25.3%
Licensing arrangements, liability	——	——	——	——	——
Litigation payment exclusion from EBITDA	——	——	——	——	——
Long-Term Debt and Lease Obligation	$10.99B+4.3%	$11.14B+24.2%	$11.12B+20.4%	$11.11B+23.5%	$10.53B+10.5%
Loss Contingency Accrual	$229M-27.5%	$242M-25.8%	$306M+22.4%	$300M+19.5%	$316M+11.7%
Noncontrolling interests in subsidiaries	$240M+3.0%	$239M+2.6%	$236M-4.8%	$235M-1.3%	$233M-3.7%
Money Market Funds At Carrying Value	——	——	——	——	——
Long-Lived Assets	$30.21B—	$29.8B—	$29.67B—	——	——
Pre-Judgement Interest	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	50M0.0%	50M0.0%	50M0.0%	50M0.0%	50M0.0%
Preferred Stock, Shares Issued	0—	0—	0—	0—	0—
Restricted cash equivalents included in Other long-term assets	——	——	$103M+32.1%	$98M+32.4%	$91M+23.0%
Share Repurchase Program, Authorized, Amount	——	——	——	——	——
Treasury stock, shares (in shares)	263.3M0.0%	263.3M0.0%	263.3M0.0%	263.3M0.0%	263.3M0.0%
Uncapped Contingent Considertation	——	——	——	——	——
Unrecognized tax benefits	$609M+18.5%	$596M+17.8%	$529M+7.3%	$531M+11.1%	$514M+10.5%
Amount that if recognized, would affect the effective tax rate or regulatory liability	$512M+18.8%	$501M+18.4%	$444M+6.5%	$447M+10.1%	$431M+9.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Boston Scientific.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Boston Scientific's total assets?: Boston Scientific (BSX) holds $44.4B in total assets, up 10.5% year over year.
How much cash does Boston Scientific have?: Boston Scientific holds $850.0M in cash and equivalents.
Can Boston Scientific cover its short-term obligations?: Its current ratio is 1.90 — current assets exceed current liabilities.
Where does Boston Scientific's balance sheet data come from?: Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.